Welcome to the e-CCO Library!

search
Search by: 
Year: Category:
DOP065: Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Panaccione1*, J.-F. Colombel2, P. Bossuyt3, F. Baert4, T. Vanasek5, A. Danalioglu6, G. Novacek7, A. Armuzzi8, W. Reinisch7, S. Johnson9, M. Buessing9, E. Neimark10, J. Petersson10, A.M. Robinson10, R.B. Thakkar10, W.-J. Lee10, M. Skup10, G. D’Haens11

Created: Thursday, 21 February 2019, 9:14 AM
DOP065: Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in Inflammatory Bowel Disease patients with primary sclerosing cholangitis; a six year experience
Year: 2017
Source: ECCO'17 Barcelona
Authors: Hartery K.
Chromoendoscopy, Colonoscopy, Dyplasia
Files: 1
DOP065: Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in inflammatory bowel disease patients with primary sclerosing cholangitis; a six year experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hartery K., Williamson K., Chapman R., Atkinson N., East J.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP066: Developing a core outcome set for fistulising perianal Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Sahnan1*, P.J. Tozer1, S.O. Adegbola1, M.J. Lee2, N. Heywood3, A.G.K. McNair4, D. Hind5, N. Yassin6, A.J. Lobo7, S.R. Brown2, S. Sebastian8, R.K. Phillips1, P.F. Lung9, O.D. Faiz1, K. Crook10, S. Blackwell11, A. Verjee12, A.L. Hart13, N.S. Fearnhead14

Created: Thursday, 21 February 2019, 9:14 AM
DOP066: Developing a Core Outcome Set for Fistulising Perianal Crohn’s Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Sahnan Kapil
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP066: Disappearance of Anti-drug Antibodies to Infliximab and Adalimumab after Addition of an Immunomodulator in Patients with Inflammatory Bowel Disease
Year: 2016
Source: ECCO'16 DOP
Authors: Strik A.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP066: Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Strik*1, G. van den Brink1, C. Ponsioen1, R. Mathot2, M. Löwenberg1, G. D’Haens1

Created: Friday, 22 February 2019, 9:49 AM
DOP066: Strict surveillance colonoscopy should be performed for the ulcerative colitis patients who underwent ileorectal anastomosis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Anzai H., Hata K., Ishihara S., Kishikawa J., Murono K., Kaneko M., Sasaki K., Yasuda K., Otani K., Nishikawa T., Tanaka T., Kiyomatsu T., Kawai K., Nozawa H., Watanabe T.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP066: Strict surveillance colonoscopy should be performed for the Ulcerative Colitis patients who underwent ileorectal anastomosis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Anzai H.
Colonoscopy, Dysplasia, UC colorectal cancer surveillance
Files: 1
DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a Tertiary IBD Centre
Year: 2016
Source: ECCO'16 DOP
Authors: Digby-Bell J.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a tertiary IBD centre
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Digby-Bell*1, B. Warner1, E. Johnston1, N. Unsworth2, Z. Arkir2, J. Sanderson1, P. Irving1

Created: Friday, 22 February 2019, 9:49 AM
DOP067: Risk of malignant and non-malignant complications of the rectal stump in patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bogaerts J.*1, Ten Hove J.R.1, Laclé M.M.2, Meij V.3, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP067: Risk of malignant and non-malignant complications of the rectal stump in patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bogaerts J.
Post-operative IBD, Dysplasia, UC colorectal cancer surveillance
Files: 1
DOP067: Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: a comparative effectiveness study of vedolizumab vs. infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Raluy-Callado1, A. Berger2, J.M. Khalid3, H. Patel3*

Created: Thursday, 21 February 2019, 9:14 AM
DOP067: Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: A comparative effectiveness study of vedolizumab versus infliximab
Year: 2018
Source: ECCO'18 Vienna
Authors: Patel Haridarshan
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP068: Crohn’s disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.A. Siegel1*, K.D. Thompson1, L.S. Siegel2, T. MacKenzie3, M.C. Dubinsky4

Created: Thursday, 21 February 2019, 9:14 AM
DOP068: Crohn’s Disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trial
Year: 2018
Source: ECCO'18 Vienna
Authors: Siegel Corey A.
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP068: Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBD
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. F. Brandse*1, D. R. Mould2, Y. K. Ashruf1, O. Smeekes1, S. Kuin1, A. Strik1, G.R. van den Brink1, G. R. D’Haens1

Created: Friday, 22 February 2019, 9:49 AM
DOP068: The virtual electronic chromoendoscopy (VEC) score in Ulcerative Colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: A study across academic and community practice
Year: 2017
Source: ECCO'17 Barcelona
Authors: Trivedi P.
Chromoendoscopy, Colonoscopy, Narrow band imaging, UC Colorectal cancer surveillance
Files: 1
DOP068: The virtual electronic chromoendoscopy score in ulcerative colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: a study across academic and community practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Trivedi P.*1,2,3,4, Hodson J.3, Bhala N.4, Cooney R.4, Boulton R.4, Gui X.5, Iqbal T.4, Li K.-k.6, Mumtaz S.7, Pathmakanthan S.4, Quraishi M.N.4, Sagar V.M.1, Shah A.7, Sharma N.8, Siau K.7, Smith S.4, Ward S.9, Widlak M.M.10,11, Ghosh S.3,4, Iacucci M.3,4

Created: Wednesday, 20 February 2019, 10:36 AM